Recruiting | Phase II
Testing combination antibody treatment with Trastuzumab and Pertuzumab for advanced or metastatic colorectal cancer.
The purpose of this study is to compare any good or bad effects of using a combination of antibodies, Trastuzumab and Pertuzumab, to treating with the usual chemotherapy, Cetuximab and Irinotecan.
- Step 1 Registration: Her-2 Amplification Screening.
- Step 2 Registration: Randomized to either Arm 1 (Trastuzumab + Pertuzumab) or Arm 2 (Cetuximab + Irinotecan).
- Step 3 Registration (for Arm 2 patients only): Optional crossover to Trastuzumab + Pertuzumab.
Key Participation Requirements:
Male or Female
19 years and older
Metastatic or locally advanced and unresectable colorectal cancer.
Must have molecular testing performed which includes KRAS and NRAS gene and exon 15 of BRAF gene.
No prior treatment with either Cetuximab or Panitumumab.
Patients must have had at least one prior regimen of systemic chemotherapy for metastatic or locally advanced, unresectable disease.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
Methodist Health System Trial Code:
For more information, visit the U.S. National Library of Medicine clinical trial database.
To learn more about this clinical trial please contact us today!